1. Search Result
Search Result
Results for "

GSH

" in MCE Product Catalog:

22

Inhibitors & Agonists

2

Dye Reagents

1

Biochemical Assay Reagents

7

Natural
Products

2

Recombinant Proteins

Cat. No. Product Name Target Research Areas
  • HY-D0187
    L-Glutathione reduced

    GSH; γ-L-Glutamyl-L-cysteinyl-glycine

    Endogenous Metabolite Reactive Oxygen Species Ferroptosis Cancer Inflammation/Immunology Neurological Disease Cardiovascular Disease
    L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.
  • HY-131013
    GSHtracer

    Others Others
    GSHtracer is a ratiometric probe for measuring of GSH levels. GSHtracer exhibits Ex/Em from 520/580 nm to 430/510 nm (upon GSH binding) .
  • HY-W010243
    Methylisothiazolinone hydrochloride

    Bacterial Infection
    Methylisothiazolinone hydrochloride is the constituent of the biocide Kathon CG. Methylisothiazolinone hydrochloride is an isothiazolone derivative widely used as a preservative. Methylisothiazolinone hydrochloride is also a moderate sensitizer and reacts with GSH.
  • HY-113402
    Gamma-glutamylcysteine

    γ-Glutamylcysteine

    Endogenous Metabolite Inflammation/Immunology
    Gamma-glutamylcysteine (γ-Glutamylcysteine), a dipeptide containing cysteine and glutamic acid, is a precursor to glutathione (GSH). Gamma-glutamylcysteine is a cofactor for glutathione peroxidase (GPx) to increase GSH levels.
  • HY-118149A
    (±)9-HpODE

    Bacterial Fungal Parasite Infection
    (±)9-HpODE is a long chain lipid hydroperoxide, is a product of linoleic acid peroxidation. (±)9-HpODE can induce oxidation of intracellular glutathione (GSH). (±)9-HpODE also exhibits antimicrobial activity against various fungal and bacterial pathogens.
  • HY-W009177
    S-Methylglutathione

    Others Others
    S-Methylglutathione is an S-substitued glutathione and a stronger nucleophile than GSH. S-Methylglutathione has inhibitory effect on glyoxalase 1.
  • HY-100609
    4-P-PDOT

    Melatonin Receptor Neurological Disease
    4-P-PDOT is a potent, selective and affinity Melatonin receptor (MT2) antagonist. 4-P-PDOT is >300-fold more selective for MT2 than MT1. 4-P-PDOT significantly counteracts Melatonin-mediated antioxidant effects (GSH/GSSG ratio, phospho-ERK, Nrf2 nuclear translocation, Nrf2 DNA-binding activity).
  • HY-N9349
    Malvidin-3-O-arabinoside chloride

    AMPK Autophagy Metabolic Disease Inflammation/Immunology
    Malvidin-3-O-arabinoside chloride ameliorates ethyl carbamate-induced oxidative damage by stimulating AMPK-mediated autophagy.
  • HY-17363
    Dimethyl fumarate

    DMF

    Keap1-Nrf2 Reactive Oxygen Species HIV Autophagy Endogenous Metabolite Cancer Infection Inflammation/Immunology Neurological Disease
    Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway, and also induces cell autophagy. Dimethyl fumarate can be used for multiple sclerosis research.
  • HY-N0244
    Theaflavin-3'-gallate

    Others Cancer
    Theaflavin-3'-gallate, a black tea theaflavin monomer, is regarded as the biologically important active component of black tea and provides health benefits. Theaflavin-3'-gallate acts as prooxidants and induces oxidative stress in the carcinoma cells. Theaflavin-3'-gallate reacts directly with reduced glutathione (GSH) in a time- and concentration-dependent manner.
  • HY-N0245
    Theaflavin-3-gallate

    Others Cancer
    Theaflavin-3-gallate, a black tea theaflavin monomer, is regarded as the biologically important active component of black tea and provides health benefits. Theaflavin-3-gallate acts as prooxidants and induces oxidative stress in the carcinoma cells. Theaflavin-3-gallate reacts directly with reduced glutathione (GSH) in a time- and concentration-dependent manner.
  • HY-106376A
    L-Buthionine-(S,R)-sulfoximine

    L-Buthionine sulfoximine; L-BSO

    Ferroptosis Cancer
    L-Buthionine-(S,R)-sulfoximine is a cell-permeable, potent, fast acting and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC50 value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively.
  • HY-106376C
    L-Buthionine-(S,R)-sulfoximine hydrochloride

    L-Buthionine sulfoximine hydrochloride; L-BSO hydrochloride

    Ferroptosis Cancer Metabolic Disease
    L-Buthionine-(S,R)-sulfoximine hydrochloride is a cell-permeable, potent, fast acting, orally active and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC50 value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively.
  • HY-106842
    Nitecapone

    OR-462

    COMT Inflammation/Immunology Neurological Disease
    Nitecapone (OR-462) is an orally active and short-acting catechol-O-methyltransferase (COMT) inhibitor with gastroprotective and antioxidant properties. Nitecapone (OR-462) scavenges reactive oxygen and nitric radicals and prevents lipid peroxidation.
  • HY-136386
    N-Acetyl-D-cysteine

    Reactive Oxygen Species Others
    N-Acetyl-D-cysteine has antioxidant activities and scavenges ROS through the reaction with its thiol group, but cannot enter the glutathione metabolic pathway.
  • HY-134495
    N-Acetyl-L-cysteine ethyl ester

    N-Acetylcysteine ethyl ester; NACET

    Reactive Oxygen Species Metabolic Disease
    N-Acetyl-L-cysteine ethyl ester is an esterified form of N-acetyl-L-cysteine (NAC). N-Acetyl-L-cysteine ethyl ester exhibits enhanced cell permeability, and produce NAC and cysteine. N-Acetyl-L-cysteine ethyl ester increases circulating hydrogen sulfide (H2S) and can be used as an H2S producer. N-Acetyl-L-cysteine ethyl ester has the potential to substitute NAC as a mucolytic agent, and as a GSH-related antioxidant.
  • HY-113402A
    Gamma-glutamylcysteine TFA

    γ-Glutamylcysteine TFA

    Interleukin Related TNF Receptor Endogenous Metabolite Inflammation/Immunology
    Gamma-glutamylcysteine (γ-Glutamylcysteine) TFA, an intermediate in glutathione (GSH) synthesis, is a dipeptide served as an essential cofactor for the antioxidant enzyme glutathione peroxidase (GPx). Gamma-glutamylcysteine TFA also upregulates the level of the anti-inflammatory cytokine IL-10 and reduces the levels of the pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β). Gamma-glutamylcysteine TFA attenuates the changes in metalloproteinase activity in oligomeric Aβ40-treated astrocytes.
  • HY-106628
    Sudoxicam

    COX Inflammation/Immunology
    Sudoxicam is a reversible and orally active COX antagonist and a non-steroidal anti-inflammatory drug (NSAID) from the enol-carboxamide class. Sudoxicam has potent anti-inflammatory, anti-edema and antipyretic activity.
  • HY-123962
    G6PD activator AG1

    Others Metabolic Disease
    G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) activator with an EC50 of 3 µΜ. G6PD activator AG1 reduces hemolysis of human erythrocytes.
  • HY-103354
    Proglumide sodium

    Cholecystokinin Receptor Cancer Endocrinology Neurological Disease
    Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities.
  • HY-103354A
    Proglumide hemicalcium

    Cholecystokinin Receptor Cancer Endocrinology Neurological Disease
    Proglumide hemicalcium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide hemicalcium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide hemicalcium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide hemicalcium also has antiepileptic and antioxidant activities.
  • HY-B1330
    Proglumide

    Cholecystokinin Receptor Cancer Endocrinology Neurological Disease
    Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities.